Fund Purpose

The WakeMed Innovation Venture Fund (WIVF) invests in early-stage healthcare companies developing technologies that improve patient outcomes, operational efficiency, and financial performance for WakeMed Health & Hospitals.

WIVF combines Hatteras’ venture discipline with WakeMed’s clinical insight and operational expertise to support early-stage companies creating transformative solutions in medical devices, diagnostics, digital health, and patient experience. This enables early-stage companies to access subject-matter experts, pursue pilot opportunities, conduct research, and validate their solutions in real-world settings.

WIVF’s mission is to accelerate innovations that deliver measurable benefits to patients, providers, and community health systems while generating competitive, venture-style returns for WakeMed as the fund’s limited partner.

Launched in 2020, WIVF was created and is managed by Hatteras Venture Partners, with the active participation of WakeMed as a strategic limited partner and Hatteras serving as the institutional fund manager.

The fund builds on more than a decade of innovation at WakeMed and over twenty-five years of healthcare-focused venture investing at Hatteras.

To date, WIVF has reviewed more than 300 early-stage healthcare opportunities and engaged over 100 WakeMed clinicians and operators in evaluations, pilots, and validation activities.

In 2025, WIVF marked its fifth anniversary, underscoring how an actively engaged community health system as a limited partner and an institutional venture firm as fund manager can work together to advance healthcare innovation.